

Figure S6 Curve diagram of SUCRA of outcome indicators




Figure S6(a) Curve diagram of SUCRA of LVEF%

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(b) Curve diagram of SUCRA of LVEDD

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(c) Curve diagram of SUCRA of LVEDV

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(d) Curve diagram of SUCRA of LVESD

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i




Figure S6(e) Curve diagram of SUCRA of LVESV

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i




Figure S6(f) Curve diagram of SUCRA of LVMI

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(g) Curve diagram of SUCRA of e'

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(h) Curve diagram of SUCRA of E/e'

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(i) Curve diagram of SUCRA of E/A

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(j) Curve diagram of SUCRA of SBP

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(k) Curve diagram of SUCRA of NT-pro BNP

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(l) Curve diagram of SUCRA of 6MWT

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i

Subgroup of patients with T2DM and CVD




Figure S6(m) Curve diagram of SUCRA of LVEF%.

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(n) Curve diagram of SUCRA of LVEDV

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(o) Curve diagram of SUCRA of LVESV

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(p) Curve diagram of SUCRA of E/e'

Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i




Figure S6(q) Curve diagram of SUCRA of SBP
 Note: 1 DDP-4i, 2 GLP-1RA, 3 Placebo, 4 SGLT-2i

Subgroup of patients with CVD alone




Figure S6(r) Curve diagram of SUCRA of LVEF%.

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i




Figure S6(s) Curve diagram of SUCRA of NT-pro BNP.

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i




Figure S6(t) Curve diagram of SUCRA of 6MWT.

Note: 1 GLP-1RA, 2 Placebo, 3 SGLT-2i

Note: **e'**: early diastolic velocity; **E/e'**: mitral inflow E velocity to tissue doppler e' ratio; **E/A**: early diastolic to late diastolic velocities ratio; **CVD**: cardiovascular disease; **DPP-4i**: dipeptidyl peptidase-4 inhibitor; **GLP-1RA**: glucagon-like peptide-1 receptor agonist; **LVEDD**: left ventricular end-diastolic diameter; **LVEDV**: LV end-diastolic volume; **LVEF**: LV ejection fraction; **LVESD**: LV end-systolic diameter; **LVESV**: LV end-systolic volume; **LVTMI**: LV mass index; **NT-pro BNP**: immunoreactive amino-terminal pro-brain natriuretic peptide; **SBP**: systolic blood pressure; **SGLT-2i**: sodium glucose cotransporter type 2 inhibitor; **T2DM**: type 2 diabetes; **6MWT**: 6-min walk test.